Jun 22, 2020
LUNGevity and EGFR Resisters Collaborate on Lung Cancer Research Awards
May 07, 2020
Bridge Biotherapeutics Announces the IND Clearance of BBT-176, an EGFR TKI for NSCLC, in South Korea
Jan 19, 2020
Bridge Biotherapeutics Announces FDA IND Clearance for BBT-176, an EGFR TKI for NSCLC
Dec 19, 2019
Bridge Biotherapeutics Files Investigational New Drug Application for BBT-176, an EGFR TKI for NSCLC
Sep 26, 2019
Black Diamond Therapeutics to Present Preclinical Data on its Lead Product Candidate BDTX-189 at the European Society for Medical Oncology 2019
Sep 10, 2019
Updated Phase 1 Data for Daiichi Sankyo's U3-1402 in Patients with EGFR Mutated NSCLC Presented at 2019 World Conference on Lung Cancer
Jun 03, 2019
Thermo Fisher Scientific's Oncomine Dx Target Test Receives Reimbursement Coverage in Japan
May 31, 2019
Daiichi Sankyo Presents Preliminary Phase 1 Data for HER3 Targeting ADC U3-1402 in Patients with EGFR Mutated Non-Small Cell Lung Cancer at 2019 ASCO Annual Meeting
Feb 26, 2019
Thermo Fisher Scientific's Oncomine Dx Target Test Receives Expanded Regulatory Approval in Japan
Nov 15, 2018
Patients Launch New Study to Shed Light on EGFR-Positive Lung Cancers
Oct 18, 2018
Daiichi Sankyo Initiates Phase 1 Study of AXL Inhibitor DS-1205 in Patients with EGFR-Mutated Metastatic Non-Small Cell Lung Cancer
Sep 26, 2018
Global survey reveals that physicians need more information to assess the impact of treatment sequencing on patient survival in EGFR mutation-positive NSCLC
Aug 23, 2018
Highmark Health's VITAL Innovation Program testing benefits of Biocept's liquid biopsy platform for improving outcomes and lowering costs of treatment for patients with non-small cell lung cancer
Apr 18, 2018
US FDA Approves TAGRISSO® (osimertinib) As 1st-Line Treatment For EGFR-Mutated Non-Small Cell Lung Cancer
Feb 06, 2018
Daiichi Sankyo Initiates Phase 1 Study of U3-1402 in Patients with Metastatic EGFR-Mutated Non-Small Cell Lung Cancer
Jan 16, 2018
FDA approves new indication for Gilotrif® in EGFR mutation-positive NSCLC
Jan 09, 2018
BerGenBio Meets First Efficacy Endpoint in Phase II Trial With Selective AXL Inhibitor BGB324 (bemcentinib) in NSCLC
Jun 22, 2017
FDA Approves First Companion Diagnostic Test to Simultaneously Screen for Multiple Non-Small Cell Lung Cancer Therapies
May 30, 2017
Global $12 Billion Non-small Cell Lung Cancer (NSCLC) Therapeutics Market Analysis 2014-2017 and Forecasts to 2025 - Research and Markets